Target intelligence / Profile preview

Alpha-galactoside-containing oligosaccharide (None commonly used)

Target
None commonly used
Molecular classification
Other (not a receptor, enzyme, transporter, etc.), Oligosaccharide, Prebiotic carbohydrate
01

Overview

Alpha-galactoside-containing oligosaccharides are a class of carbohydrates characterized by terminal α-galactosyl linkages to other monosaccharides, typically glucose or fructose.[1][2] Common examples include raffinose and stachyose (collectively known as raffinose family oligosaccharides) and various forms of galacto-oligosaccharides (GOS) synthesized by enzymatic processes. These molecules are not receptors, enzymes, or canonical drug targets, but serve as prebiotics: when ingested, they selectively stimulate the growth and activity of beneficial gut bacteria such as Bifidobacterium and Lactobacillus, modulating the gut microbiome, lipid metabolism, immune responses, and intestinal barrier function.[2][4] Some α-galactoside-containing oligosaccharides are naturally present in legumes and other plant foods, contributing to dietary fiber content, while others can be formulated as dietary supplements. Their bioactivity is mediated by fermentation and selective utilization by gut microbes, not by interaction with drug molecules or direct receptor/enzyme targeting. Important note: "Alpha-galactoside-containing oligosaccharides" refers to a class of carbohydrates, not a molecular drug target, receptor, or enzyme. They are sometimes substrates for specific enzymes (e.g., alpha-galactosidase) but are not themselves canonical targets for therapeutics.[1][2][4]

Other names
α-galactoside-containing oligosaccharideAlpha-galacto-oligosaccharideα-GOS (sometimes seen as an abbreviation for α-galacto-oligosaccharides)RFOs (Raffinose family oligosaccharides, subfamily containing α-galactosidic linkages)Galacto-oligosaccharide (GOS; includes but is not exclusive to α-galactoside linkages)
02

Mechanism of action

Serve as prebiotics: fermented by gut bacteria to produce short-chain fatty acids, change microbiome composition. Can inhibit pathogenic bacterial adhesion by occupying binding sites in the intestine. Modulate host metabolism through gut microbial metabolites

03

Biological functions

Prebiotic activity (promotes growth of beneficial gut bacteria, such as Bifidobacterium and Lactobacillus)Regulation of gut microbiota (modifies microbial composition, antagonizes pathogenic bacteria)Immunomodulation (modulates innate and adaptive immune response via gut flora)Alters carbohydrate and lipid metabolismSupports intestinal barrier function
04

Disease associations

Other (not a direct causative agent, but implicated in)Metabolic disorders (may ameliorate obesity, hepatic steatosis, and metabolic syndrome)Inflammatory diseases (shown beneficial effect in animal models of colitis/ulcerative colitis)Allergic diseases (some evidence for benefit in atopic dermatitis, via microbiome modulation)
05

Safety considerations

Typically regarded as safe; however, can cause flatulence or mild gastrointestinal discomfort in some individuals, especially at high intakeNot appropriate for individuals with galactosemia or severe carbohydrate malabsorptionNo major toxicity or drug interaction profile as these are dietary carbohydrates, not pharmaceuticals
06

Biomarkers

Increase in beneficial bacteria (primarily Bifidobacterium, Lactobacillus count)Decrease in harmful gut bacteria (e.g., Clostridium leptum group)Short-chain fatty acid (SCFA) levels (produced from oligosaccharide fermentation)

Beyond the preview

Go deeper on Alpha-galactoside-containing oligosaccharide (None commonly used).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-galactoside-containing oligosaccharide (None commonly used).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call